The baseline HF treatments included beta-blockers (70.1%), renin–angiotensin system inhibitors (56.3%), mineralocorticoid receptor antagonists (11.8%), and sodium–glucose cotransporter-2 inhibitors (SGLT2is) (8.9%). Here, NR3C2 is linked to hydrops fetalis.